A
AKTS
Aktis Oncology, Inc. Common stock
$16.49
Current Price
1W
1M
3M
6M
1Y
All
AI analysis
Read what the AI thinks of Aktis Oncology, Inc. Common stock in the app.
Analyses are generated by AI from public data and are not investment advice.
Get the app
Key figures
Dividend per share
—
Yield
—
EPS
-$2.07
P/E
—
Data as of Oct 8
Why it matters for the long term
Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.
Posts
No posts about AKTS yet.
About Aktis Oncology, Inc. Common stock
Aktis Oncology is a clinical-stage biotech company based in the US that develops cancer drugs. It has no approved medicines yet, so it earns almost no revenue and pays its bills with money raised from investors. The business only pays off if its experimental treatments pass trials and win regulatory approval.